Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®

Stock Information for Evoke Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evoke Pharma Inc.

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025
Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025
Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.